Stockscreener 앱 받기
3.2457
2.82%
0.0857
전일 마감가:
$3.16
열려 있는:
$3.15
하루 거래량:
70,663
Relative Volume:
0.09
시가총액:
$270.78M
수익:
$380.79M
순이익/손실:
$49.27M
주가수익비율:
4.6367
EPS:
0.7
순현금흐름:
$10.68M
1주 성능:
-1.54%
1개월 성능:
-5.82%
6개월 성능:
+55.46%
1년 성능:
-83.40%
1일 변동 폭
$3.105
$3.27
1주일 범위
$2.865
$3.40
52주 변동 폭
$1.575
$19.95
Amylyx Pharmaceuticals Inc Stock (AMLX) Company Profile
명칭
Amylyx Pharmaceuticals Inc
전화
617-683-0917
주소
43 THORNDIKE STREET, CAMBRIDGE
AMLX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AMLX
Amylyx Pharmaceuticals Inc
|
3.245 | 270.78M | 380.79M | 49.27M | 10.68M | 0.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
478.26 | 121.85B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
699.75 | 76.83B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
623.27 | 37.96B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.59 | 30.69B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beone Medicines Ltd Adr
|
269.40 | 29.71B | 3.32B | -860.46M | -1.04B | -8.32 |
Amylyx Pharmaceuticals Inc Stock (AMLX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-18 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2024-10-23 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-03-18 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2024-03-11 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-03-11 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-03-08 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2024-03-08 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-01-03 | 개시 | Robert W. Baird | Outperform |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-07-24 | 업그레이드 | Goldman | Neutral → Buy |
| 2023-03-31 | 개시 | Mizuho | Buy |
| 2023-01-05 | 개시 | BofA Securities | Buy |
| 2022-05-25 | 개시 | Citigroup | Buy |
| 2022-04-01 | 다운그레이드 | Goldman | Buy → Neutral |
모두보기
Amylyx Pharmaceuticals Inc 주식(AMLX)의 최신 뉴스
Shareholders that lost money on Amylyx Pharmaceuticals, Inc.(AMLX) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
Amylyx Pharmaceuticals, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before April 9, 2024 to Discuss Your RightsAMLX - ACCESS Newswire
Top Executive Sells Thousands in Amylyx Pharmaceuticals Stock! - TipRanks
Amylyx Pharmaceuticals to Participate in Upcoming March Investor Conferences - Business Wire
Amylyx Pharmaceuticals: Lots Of Setbacks, Some Chances Of Recovery - Seeking Alpha
Q4 Earnings Preview: Can Amylyx Pharmaceuticals Deliver Strong 2024 Results? - StockTitan
Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on March 4, 2025 - The Bakersfield Californian
Class Action Filed Against Amylyx Pharmaceuticals, Inc. (AMLX)April 9, 2024 Deadline to Join – Contact Levi & Korsinsky - accessnewswire.com
IMMINENT AMLX DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Amylyx Pharmaceuticals, Inc. Investors to Join the Class Action Lawsuit! - ACCESS Newswire
Shareholders of Amylyx Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before April 9, 2024 to Discuss Your Rights – AMLX - ACCESS Newswire
Levi & Korsinsky Reminds Amylyx Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 9, 2024AMLX - ACCESS Newswire
Amylyx Pharmaceuticals (AMLX) to Release Earnings on Thursday - MarketBeat
Amylyx Pharmaceuticals (AMLX) to Release Quarterly Earnings on Thursday - Defense World
UPCOMING AMLX DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Amylyx Pharmaceuticals, Inc. Investors to Join the Class Action Lawsuit! - ACCESS Newswire
FDA clears Amylyx to resume ALS drug trial in North America - MSN
AMLX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Amylyx Pharmaceuticals, Inc. Investors to Join the Class Action Lawsuit! - ACCESS Newswire
FDA lifts clinical hold on Amylyx’s Phase I ALS trial - MSN
AMLX SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Amylyx Pharmaceuticals, Inc. Investors to Join the Class Action Lawsuit! - ACCESS Newswire
DEADLINE ALERT: Bernstein Liebhard LLP Reminds Amylyx Pharmaceuticals, Inc. Investors of Upcoming Deadline - ACCESS Newswire
The Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market: A Comprehensive Overview and Future Outlook - EIN News
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Receives Average Rating of “Moderate Buy” from Analysts - Armenian Reporter
Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Shareholders to Inquire about Securities Investigation - Markets Insider
SG Americas Securities LLC Reduces Holdings in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - Defense World
Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Shareholders to Connect - Markets Insider
There is no doubt that Amylyx Pharmaceuticals Inc (AMLX) ticks all the boxes. - SETE News
2025-02-13 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Shareholders to Connect | NDAQ:AMLX | Press Release - Stockhouse Publishing
AMLX 3-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Amylyx Pharmaceuticals (AMLX) Investors with Substantial Losses to Contact Firm Before Apr. 9th Deadline in Securities Fraud Class Action - ACCESS Newswire
abrdn plc Sells 249,437 Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - MarketBeat
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Shareholders to Reach Out - Markets Insider
Analysts Set Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Price Target at $7.33 - Defense World
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Shareholders to Learn More About the Investigation - Markets Insider
Amylyx Pharmaceuticals Inc (AMLX) presents a great opportunity, but the stock is slightly undervalued - US Post News
Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Stockholders to Inquire about Securities Investigation - Markets Insider
2025-02-10 | Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Stockholders to Inquire about Securities Investigation | NDAQ:AMLX | Press Release - Stockhouse Publishing
Amylyx Pharmaceuticals Inc [AMLX] Stock sold by Insider Mazzariello Gina for $12839.0 - Knox Daily
Amylyx Pharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference - The Bakersfield Californian
Amylyx (AMLX) Sets Stage for Major Strategic Updates at Premier Healthcare Conference - StockTitan
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Insider Gina Mazzariello Sells 3,678 Shares - MarketBeat
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) CEO Sells $41,122.97 in Stock - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Investors to Learn More About the Investigation - Markets Insider
Following A 4.11% Weekly Incline, Is It Still A Buy For Amylyx Pharmaceuticals Inc (NASDAQ: AMLX)? - Marketing Sentinel
Insider Selling: Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Insider Sells $12,836.22 in Stock - Armenian Reporter
Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - Markets Insider
Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Investors to Connect - Markets Insider
Amylyx Pharmaceuticals' co-CEO Justin Klee sells $41,103 in shares - MSN
Taking on analysts’ expectations and winning: Amylyx Pharmaceuticals Inc (AMLX) - SETE News
Amylyx Pharmaceuticals' co-CEO Justin Klee sells $41,103 in shares By Investing.com - Investing.com Canada
Amylyx Pharmaceuticals’ co-CEO Justin Klee sells $41,103 in shares By Investing.com - Investing.com Nigeria
Amylyx Pharmaceuticals Executives Cash In on Stock Sales - TipRanks
Research Analysts Set Expectations for AMLX FY2025 Earnings - MarketBeat
Amylyx Pharmaceuticals Inc (AMLX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Amylyx Pharmaceuticals Inc 주식 (AMLX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Klee Justin B. | Co-Chief Executive Officer |
Feb 05 '25 |
Option Exercise |
1.57 |
36,310 |
57,007 |
3,201,243 |
| Mazzariello Gina | Chief Legal Officer |
Feb 03 '25 |
Sale |
3.49 |
3,678 |
12,839 |
139,090 |
| Cohen Joshua B | Co-Chief Executive Officer |
Feb 03 '25 |
Sale |
3.47 |
11,851 |
41,108 |
3,201,247 |
| Klee Justin B. | Co-Chief Executive Officer |
Feb 03 '25 |
Sale |
3.47 |
11,855 |
41,104 |
3,164,933 |
| Klee Justin B. | Co-Chief Executive Officer |
Jan 06 '25 |
Sale |
4.04 |
7,471 |
30,202 |
3,176,788 |
| Cohen Joshua B | Co-Chief Executive Officer |
Jan 06 '25 |
Sale |
4.05 |
7,471 |
30,232 |
3,213,098 |
| Bedrosian Camille L | Chief Medical Officer |
Dec 02 '24 |
Sale |
5.54 |
5,421 |
30,007 |
138,380 |
| Klee Justin B. | Co-Chief Executive Officer |
Nov 04 '24 |
Option Exercise |
1.57 |
63,690 |
99,993 |
3,184,259 |
| Klee Justin B. | Co-Chief Executive Officer |
Sep 30 '24 |
Sale |
3.20 |
18,589 |
59,429 |
3,120,569 |
| Cohen Joshua B | Co-Chief Executive Officer |
Sep 30 '24 |
Sale |
3.20 |
18,589 |
59,414 |
3,220,569 |
2.09%
0.69%
자본화:
|
볼륨(24시간):